Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety

Vaccine

Volumn 32, Issue 34, 2014, Pages 4275-4280

  Beran, Jiří ^a   Xie, Fang ^b   Zent, Olaf ^c  

^a Vaccination and Travel Medicine Centre   (Czech Republic)

^b MS X 600A   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Booster immunization; Immunogenicity; Persistence; Tick borne encephalitis

Indexed keywords

ANTIBODY; TICK BORNE ENCEPHALITIS VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SERODIAGNOSIS; SUICIDE; TICK BORNE ENCEPHALITIS; VACCINATION; BLOOD; CLINICAL TRIAL; ENCEPHALITIS, TICK-BORNE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ENCEPHALITIS, TICK-BORNE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VIRAL VACCINES; YOUNG ADULT;

EID: 84903818477     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.028     Document Type: Article

References (21)

1. WHO Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 2011, 24:241-256.
2. Novartis Vaccines and Diagnostics GmbH & Co. KG. Encepur Erwachsene summary of product characteristics/Fachinformation 2008.
3. Zent O., Beran J., Jilg W., Mach T., Banzhoff A. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine 2003, 21:738-741.
4. Zent O., Banzhoff A., Hilbert A.K., Meriste S., Sluzewski W., Wittermann C. Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine 2003, 21:3584-3592.
5. Zent O., Jilg W., Plentz A., Schwarz T.F., Fruhwein N., Kuhr H.B., et al. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 2003, 21:4655-4660.
6. Schondorf I., Beran J., Cizkova D., Lesna V., Banzhoff A., Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 2007, 25:1470-1475.
7. Plentz A., Jilg W., Schwarz T.F., Kuhr H.B., Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults. Vaccine 2009, 27:853-856.
8. Litzba N., Zelena H., Kreil T.R., Niklasson B., Kuhlmann-Rabens I., Remoli M.E., et al. Evaluation of different serological diagnostic methods for tick-borne encephalitis virus: enzyme-linked immunosorbent, immunofluorescence, and neutralization assay. Vector-Borne Zoonotic Dis 2014, 14:1-11.
9. Kollaritsch H., Paulke-Korinek M., Holzmann H., Hombach J., Bjorvatn B., Barrett A. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines 2012, 11:1103-1119.
10. Amicizia D., Domnich A., Panatto D., Lai P.L., Cristina M.L., Avio U., et al. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccines Immunother 2013, 9:1163-1171.
11. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Laaber B., Wiedermann U., Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine 2009, 27:7027-7030.
12. Rendi-Wagner P., Paulke-Korinek M., Kundi M., Wiedermann U., Laaber B., Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 2007, 25:5097-5101.
13. Rendi-Wagner P., Kundi M., Zent O., Dvorak G., Jaehnig P., Holzmann H., et al. Persistence of protective immunity following vaccination against tick-borne encephalitis-longer than expected?. Vaccine 2004, 22:2743-2749.
14. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Koska M., Bobrovsky R., et al. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5ml in adults aged 18-67 years. Hum Vaccin 2009, 5:551-556.
15. Schondorf I., Schonfeld C., Nicolay U., Zent O., Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule. Int J Med Microbiol: IJMM 2006, 296(Suppl 40):208-212.
16. Zent O., Plentz A., Schwarz T.F., Fruhwein N., Kuhr H.B., Broeker M., et al. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?. Vaccine 2004, 23:312-315.
17. Beran J., Douda P., Gniel D., Zent O. Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule. Int J Med Microbiol: IJMM 2004, 293(Suppl 37):130-133.
18. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Firth C., Petermann R., et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 2011, 29:7307-7319.
19. Rendi-Wagner P., Kundi M., Zent O., Banzhoff A., Jaehnig P., Stemberger R., et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 2004, 23:427-434.
20. Rendi-Wagner P., Zent O., Jilg W., Plentz A., Beran J., Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol: IJMM 2006, 296(Suppl 40):202-207.
21. Schosser R., Reichert A., Mansmann U., Unger B., Heininger U., Kaiser R. Irregular tick-borne encephalitis vaccination schedules: the effect of a single catch-up vaccination with FSME-IMMUN. A prospective non-interventional study. Vaccine 2014, 32:2375-2381.